drugset
Drugs / S2/S15domV/CpG40
last change Oct 2017 re-read 3 minutes ago

S2/S15domV/CpG40

Developed for
poliomyelitis
Investigated by
Bill and Melinda Gates Foundation · Celerion · Centers for Disease Control and Prevention · PATH · Pierre Van Damme

Trials 1

today NCT03430349 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03430349 May → Sep 2017 poliomyelitis Pierre Van Damme Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as S2/S15domV/CpG40 “Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).” NCT03430349 ↗
Route Oral “administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50)” NCT03430349 ↗